The RegMed sector is like a martini, stirred but not shaken

10:08:15 AM EDT, Saturday, July 13, 2013 · Henry McCusker / Scimitar Equity

However, with a “chilled” investor glass The RegMed sector on “TGIF” … squeezed out small gains in most cases. I still believe it feels like a huge short-covering – could ...


A reverse split reduces the ratio of over-hangs

12:11:15 PM EDT, Friday, July 12, 2013 · Henry McCusker / Scimitar Equity

The 6 W’s: Who, what, where, when, why and what of it RegMed equities struggled for direction Friday, as investors took a breather. Universe companies must be concerned <the new ...


The Early Movers – who’s hot, who’s not…

10:44:53 AM EDT, Friday, July 12, 2013 · Henry McCusker / Scimitar Equity

Which RegMed companies are making moves in the 1st hour?                                      The RegMed Scoreboard UPS DOWNS FLATS   14 15 13         EQUITY SYMBOL PRICE CHANGE   ...


NeoStem (NYSE MKT: NBS) 1-for-10 Reverse Split – BUY

8:23:02 AM EDT, Friday, July 12, 2013 · Henry McCusker / Scimitar Equity

     Focuses market pricing to peers and comparables   NeoStem, Inc. (NYSE MKT: NBS) effected a 1-for-10 reverse stock split of its common stock which will be effective for ...


Mixed to higher open anticipated

6:48:09 AM EDT, Friday, July 12, 2013 · Henry McCusker / Scimitar Equity

Stocks dip ahead of bank results and consumer data Stock-market futures log … small losses on Friday ahead of results from 3 banking giants along with producer prices and consumer ...


Who’s got the dice?

4:31:14 PM EDT, Thursday, July 11, 2013 · Henry McCusker / Scimitar Equity

Still playing the board game complicated by short covering?  The RegMed sector is still like yesterday’s board game of “Chutes and Ladders” where it seems – shorts are covering as ...


A beginning, Pharma is finally stepping up on stem cell therapies

3:01:06 PM EDT, Thursday, July 11, 2013 · Henry McCusker / Scimitar Equity

Encouraged by the positive clinical data GlaxoSmithKline Plc  (GSK GB – London) and (OTC QB: GAXF) is considering licensing 2 stem-cell gene therapies for rare diseases from an Italian research group ...


Pluristem (PSTI) German P1/2 Muscle Injury Trial

2:34:58 PM EDT, Thursday, July 11, 2013 · Henry McCusker / Scimitar Equity

   Study conducted in Germany, not US   PSTI has completed the target enrollment in a randomized, double-blinded, placebo controlled P1/2 clinical trial to assess the safety and efficacy of ...


Celgene (CELG) Revlimid Slows Myeloma Progression after Stem Cell Transplant

2:15:14 PM EDT, Thursday, July 11, 2013 · Henry McCusker / Scimitar Equity

Maintenance therapy with Revlimid® reduced risk The UK’s National Institute for Health and Clinical Excellence (NICE) says it doesn’t recommend CELG’s Revlimid (lenalidomide) for treating myelodysplastic syndromes. However, maintenance therapy ...


Time to address (not dress) the elephant in the room…

12:23:48 PM EDT, Thursday, July 11, 2013 · Henry McCusker / Scimitar Equity

The 6 W’s: Who, what, where, when, why and what of it  For weeks, I have been “commenting” on the need for communication between RegMed companies and the investment community.  ...